Approximately 1 of every 250 newborns has some abnormality of genital and/or gonadal development. However, a specific molecular cause is identified in only 20% of these cases of disorder of sex development (DSD). We identified a family of French origin presenting with 46,XY DSD and congenital heart disease. Sequencing of the ORF of GATA4 identified a heterozygous missense mutation (p.Gly221Arg) in the conserved N-terminal zinc finger of GATA4. This mutation was not observed in 450 ancestry-matched control individuals. The mutation compromised the ability of the protein to bind to and transactivate the anti-Müllerian hormone (AMH) promoter. The mutation does not interfere with the direct protein-protein interaction, but it disrupts synergistic activation of the AMH promoter by GATA4 and NR5A1. The p.Gly221Arg mutant protein also failed to bind to a known protein partner FOG2 that is essential for gonad formation. Our data demonstrate the key role of GATA4 in human testicular development.
H uman disorders of sex development (DSD) are congenital conditions in which the development of chromosomal, gonadal, or anatomical sex is atypical (1) . 46,XY DSD includes errors of testis determination and differentiation (complete or partial gonadal dysgenesis), or undervirilization or undermasculinization of an XY male (1) . Despite the considerable advances in our understanding of the genetic components of gonad development, the mechanisms involved in human sex determination remain poorly understood. This is reflected in the relative paucity of pathogenic mutations that have been identified in DSD patients. It has been estimated that a molecular diagnosis is made in only 20% of DSD cases, except where the biochemical profile indicates a specific steroidogenic block (1) .
GATA4 belongs to the evolutionarily conserved GATA family of six tissue-and organ-specific vertebrate transcriptional regulators, consisting of two zinc fingers (2, 3). The C-terminal zinc finger region is required for the recognition and binding of DNA, and the N-terminal zinc finger region contributes to the stability of this binding (3) . The zinc fingers are also crucial for proteinprotein interactions with other transcription cofactors (2, 3) . In the mouse and human, GATA4 is strongly expressed in the somatic cell population of the developing gonad before and during the time of sex determination (4) . GATA4 cooperatively interacts with several proteins, including NR5A1 and FOG2, to regulate the expression of the sex-determining genes SRY (encoding sex-determining region Y), SOX9 (encoding SRY box 9), AMH (encoding anti-Müllerian hormone), as well as key steroidogenic factors, including STAR (encoding steroidogenic acute regulatory protein), CYP19A1 (encoding aromatase), INHA (encoding inhibin α-subunit), and HSD3B2 (encoding hydroxy-δ-5-steroid dehydrogenase, 3 β-and steroid δ-isomerase 2) (5-7).
Mice lacking Gata4 die in utero due to profound abnormalities in ventral morphogenesis and heart tube formation (8, 9) . In the human, mutations in GATA4 are associated with congenital heart defects (CHD), including atrial septal defects, ventricular septal defects, pulmonary valve thickening, or insufficiency of the cardiac valves (10) (11) (12) (13) . In all of the cases of CHD associated with mutations in GATA4, other organs were reported as normal.
The critical role for GATA4 in gonadal development is highlighted by Gata4 ki mice that have a p.Val217Gly mutation in the N-terminal zinc finger domain (14) . This knock-in mutation abrogates the interaction of GATA4 with the cofactor FOG2, and these animals display severe anomalies of testis development (15, 16) . FOG2 may act as a transcriptional repressor or activator, depending on the cellular and promoter context. Mice lacking Fog2 exhibit a block in gonadogenesis, and a translocation involving FOG2 in the human is reported to be associated with male hypergonadotropic hypogonadism (15) (16) (17) . In vitro FOG2 represses GATA4-dependent transcription of AMH in primary Sertoli cell cultures (18) . Although the mechanism of FOG-2 and GATA4 interaction in the gonad is not well defined, it is essential that a direct physical interaction between GATA4 and FOG2 be maintained, because abrogation of the same results in abnormal testis development in mice (14) (15) (16) . NR5A1, also termed Ad4 binding protein (Ad4BP) or steroidogenic factor 1 (SF-1), is a key transcriptional regulator of genes involved in sexual development, many of which are also regulated by GATA4 (19) (20) (21) . Mutations in NR5A1 are associated with 46,XX ovarian insufficiency and 46,XY DSD (22, 23) . GATA4 functionally interacts with NR5A1 in primary Sertoli cell cultures to positively regulate the expression of AMH, through two complementary mechanisms, either by binding to its site on the AMH promoter or by direct interaction with NR5A1 when either NR5A1 alone or both GATA4 and NR5A1 are bound to their respective sites on the AMH promoter (18) . Mutations in NR5A1 may cause 46,XY DSD through a lack of appropriate interaction with GATA4 (24) . No mutations in GATA4 have been reported in association with human cases of DSD. The absence of an associated gonadal anomaly in the reported cases of CHD associated with GATA4 mutations may also be due to the ability of the mutated GATA4 proteins to retain the ability to interact with either FOG2 or NR5A1 or both (15) (16) (17) (18) 25) .
Here, we describe a familial case of 46,XY DSD and CHD associated with a heterozygous GATA4 p.Gly221Arg mutation. This mutation in GATA4 is associated with 46,XY DSD, and the data suggest that DNA-binding activity of GATA4 is essential for transcriptional activation of the AMH promoter.
Results
Clinical Spectrum in a French Family with 46,XY DSD and CHD. The family studied is of French ethnic origin (Fig. 1A) . The three affected male patients had 46, XY karyotype and normal parameters at birth. The index case (IV.2) was referred at birth for ambiguous external genitalia (Table 1) . Genitography showed a 15-mm-diameter cavity communicating with urethra at the level of veru montanum and no uterus. Plasma concentrations of adrenal steroids before and 1 h after synthetic adreno-corticotropic hormone were within the normal range. At 40 d and at 1 y, the patient was given 30 mg of testosterone enanthate i.m. four times each 14 d, leading to an increase in phallus size and to pubic hair development. At 1 y, he was operated on for cryptorchidism. This revealed a bilateral disjunction between the epididymus and testis and a perforation in the left albuginea. At 1.5 y, urethroplasty was performed. At 10 y, testicular ultrasonography revealed diffuse calcifications. At 20 y, he is a sexually active male with height of 186 cm and weight 77 kg. He has azoospermia. There was no clinical evidence of heart anomalies by echocardiogram assessment (data available upon request).
His brother (IV.1) had decreased phallus length and inguinal hernias at birth (Table 1) . He was operated on at 2.8 y for bilateral inguinal hernias, and a minor systolic murmur was noted, suggesting an atrial septal defect. At 10.5 y, he was evaluated because of the ambiguous external genitalia seen in his brother (IV.2). His external genitalia were normal with pubic hair development. At 12.5 y, testicular ultrasonography revealed calcifications. At 18 y, a systematic cardiac evaluation was performed because of the previous systolic murmur. Doppler echocardiography revealed a normal left ventricle and a slightly dilated hypokinetic right ventricle. There were no cardiac rhythm anomalies, pulmonary pressure was normal, and there was no evidence of atrial septal defect. At 22.8 y, he is a sexually active male with height of 178 cm and weight 68 kg.
Case IV.3 was referred at 26 d for ambiguous external genitalia (Table 1) . Genitography showed a cavity of 15 × 8 mm communicating with the urethra at the level of veru montanum and no uterus. A minor systolic murmur was noted that did not require medical intervention. At 7 mo, he was operated on for bilateral inguinal hernias. The gonads measured 4 mm at their largest and were surrounded by an epidydimus and vas deferens. They were removed, and histological examination revealed bilateral dysgenetic testes. At 9 mo, he was given testosterone, and urethroplasty was performed at 2 y. At 16 y, his height is 177 cm and weight 60 kg and he is undergoing substitutive testosterone replacementtherapy.
Case IV.4 was diagnosed at birth with tetralogy of Fallot and received corrective surgery. She is now 10 y and in good health. Case III.11 was noted at birth to have congenital cyanotic heart disease. This was well tolerated, and medical intervention was not required. She has two healthy daughters and one son with no history of medical intervention.
Heterozygous GATA4 Mutation in the N-Terminal Zinc Finger. We identified a heterozygous c.661G<A transition that is predicted to result in a p.Gly221Arg mutation in the highly conserved N-terminal zinc finger domain of GATA4 (Fig. 1B) . This mutation was initially detected in the proband (IV.2) and was identified in affected brother (IV.1) and his affected cousin (IV.3). Further investigation of the family revealed that the apparently unaffected mothers (III.5 and III.9) also carried the mutation. DNA samples from other family members were not available for study. Sequencing of the entire GATA4 ORF in 450 unrelated, healthy control samples of European descent that included 342 individuals of French ancestry showed no rare allelic variants, including the mutation in this family. To exclude a role of other known sex-determining genes, we sequenced the coding regions and intron-exon boundaries of the Doublesex and Mab-3-related transcription factor 1 (DMRT1), sex-determining region Y (SRY), SRY-box 9 (SOX9), nuclear receptor subfamily 5, group A, member 1 (NR5A1), nuclear receptor subfamily 5, group A, member 2 (NR5A2), Wilms tumor 1 (WT1), and mastermind-like domain containing 1 (MAMLD1) in case IV.2 and his affected brother case IV.1. Pathogenic mutations were not detected in any of these known sex-determining genes. Discrete chromosomal rearrangements are known to be associated with 46,XY DSD (26) . Highresolution comparative genomic hybridization indicated that case IV.2 did not carry any rearrangement in his genome known to be associated with 46,XY DSD (such as del9p, del10q, dupXp, etc.).
GATA4 p.Gly221Arg Variant Does Not Affect Nuclear Localization but
Exhibits Altered DNA Binding and Transactivation Abilities. To assess the impact of the GATA4 p.Gly221Arg mutation on cellular localization, a protein expression vector was constructed by cloning mouse full-length GATA4 cDNA into the pIRES-hrGFP II vector. The GATA4 expression vector containing the p.Gly221Arg variant was generated by site-directed mutagenesis of the WT GATA4 construct. The presence of the IRES element in the vector allows the coexpression of either WT GATA4 or GATA4 p. Gly221Arg with hrGFP (human recombinant GFP) from a single transcriptional unit. Both the WT and mutant GATA4 proteins (green), when expressed in human embryonic kidney HEK 293-T cells, showed strong nuclear localization ( Fig. 2A) . The p.Gly221Arg mutation falls within the highly conserved Nterminal zinc finger domain, a region that is known to contribute to the stability of DNA binding. We hypothesized that as a consequence of this mutation, the protein may have altered DNA binding activity. To test this hypothesis, we performed EMSA, which showed WT GATA4 binding to the GATA4-responsive element on the AMH promoter, whereas the p.Gly221Arg mutant failed to bind to this motif (Fig. 2B) . The mutant GATA4 protein had altered biological activity in luciferase reporter assays driven by GATA4-dependent gonadal promoters. A quantitative reduction in transactivation of the AMH promoter was observed in reporter assays using HEK293-T cells (Fig. 2C) . These in vitro functional assays demonstrated that p.Gly221Arg mutation may lead to a functional disruption of the GATA4 protein and may affect the regulation of its downstream target genes during testis development and function.
GATA4 p.Gly221Arg Physically Interacts with NR5A1 but Fails to
Interact with FOG2. To further investigate the functional consequences of the p.Gly221Arg mutation on GATA4 protein, we analyzed the ability of the WT and mutant GATA4 to physically interact with the protein partners NR5A1 and FOG2. The GATA4 WT, GATA4p.Gly221Arg, NR5A1, and FOG2 proteins were in vitro translated. Equivalent amounts of WT and mutant GATA4 proteins were fractionated on a 10% SDS/PAGE gel and transferred to nitrocellulose membrane. The immobilized proteins were incubated with in vitro translated bait protein (either NR5A1 or FOG2), and bound bait was detected with antibait antibodies, followed by secondary antibody conjugated with HRP and visualized by chemiluminescence. In multiple experiments, the far Western analyses revealed that both the WT and mutant GATA4 proteins retained their ability to interact with NR5A1 (Fig. 3A) , but the mutant p.Gly221Arg GATA4 protein failed to interact with the FOG2 protein (Fig. 3B) . This is a similar finding to the Gata4 ki mice that have a p.Val217Gly mutation in the N-terminal zinc finger domain that also lacks the ability to interact with FOG2 (14, 15).
GATA4 p.Gly221Arg Does Not Synergize with NR5A1 to Stimulate
Reporter Gene Activity. GATA4 binds to NR5A1 to synergistically enhance the expression of AMH by regulating its promoter (24) . We studied the ability of p.Gly221Arg mutant to retain this synergy. Although the mutant protein retained the ability to physically interact with the NR5A1 protein, it showed a statistically significant reduction (P = 0.00652300) in the ability to boost AMH reporter gene activity above the levels achieved by NR5A1 alone in HEK 293T cells (Fig. 3 A and C) or using the murine ES cell line E14 (data available upon request). The mutation therefore disrupts the synergy between GATA4 and NR5A1 for activation of the AMH gene.
GATA4 p.Gly221Arg Does Not Show Dominant Negative Activity. The mutation in this family is heterozygous, and we investigated if the mutant GATA4 p.Gly221Arg may be pathogenic by being dominant negative on the WT GATA4 protein function. The GATA4 p.Gly221Arg mutant does not inhibit or interfere with the ability of WT GATA4 allele to transactivate the AMH promoter (Fig. 4A) or suppress the synergy between WT GATA4 and NR5A1 to transactivate the AMH promoter (Fig. 4B) , indicating that the mutant protein does not exhibit dominant negative activity.
Discussion
We identified a missense mutation in GATA4 associated with a familial case of 46,XY DSD and congenital heart disease. This was not observed in over 800 ancestry-matched alleles, suggesting that the mutation is associated with the phenotype. Results of the functional analyses of biological activity of the mutant protein sup- 5) or mutant GATA4 (lanes 6-10) was performed using 32 P-radiolabeled probe corresponding to the GATA4 response elements in the AMH promoter. WT GATA4 binds to the AMH promoter, and the binding is specific as indicated by the effective competition of a 100-fold excess of the unlabeled AP-1 probe (lane 5). The mutant GATA4 p.Gly221Arg protein does not bind to the AMH promoter. Controls consist of the probe alone (lane 11) and master mix from the TNT TM coupled transcription-translation system (lane 12; Promega). (C) Transcriptional activation of AMH promoter construct by GATA4. The transcriptional activities of WT GATA4 and mutant GATA4 p. Gly221Arg were studied using the human AMH promoter as a reporter following transfection in HEK293-T cells. The data shown here represent the mean ± SEM of three independent experiments, each of which was performed in triplicate. The human AMH reporter construct was transfected into HEK293-T cells with either the WT GATA4 or the mutant GATA4 expression vector. The results are expressed as a percentage of WT GATA4 activity. port this hypothesis. Though the p.Gly221Arg protein localized to the nucleus, it lacked DNA-binding activity and showed severely impaired transactivation of the AHM promoter. Although the mutant protein retained its ability to physically interact with NR5A1, it failed to synergize with NR5A1 to activate the AMH promoter. In addition, the GATA4 p.Gly221Arg failed to physically bind to one of its known protein cofactors, FOG2. This is remarkably similar to the observations in mice carrying a Gata4 ki allele that encodes a mutant Gata4 p.V217G protein. The Gata4 p.V217G protein cannot interact with FOG2, and Gata4 ki/ki XY embryos show severe impairment of testis development (15, 16) . A number of previously described GATA4 mutations specifically associated with congenital heart defects were studied for their ability to transactivate gonadal promoters (25) . In contrast to the mutation described here, these mutant proteins retained at least some DNA-binding activity and showed various degrees of transcriptional activation of the gonadal promoters. These mutant proteins also retained their ability to synergize with NR5A1 (25) . This may explain the apparent absence of gonadal anomalies reported in the individuals carrying these mutations (25) . Although to date, gonadal anomalies have not been reported in association with GATA4 mutations in human, deletions of 8p encompassing the GATA4 gene are associated with genitourinary anomalies in a proportion of XY individuals (27) .
GATA4 regulates the expression of multiple genes coding for hormones or components of the steroidogenic pathway during testis development and function. The phenotype observed in the three affected boys could be a primary defect in Sertoli cell function. This is supported by the observation that one of the boys had bilateral dysgenetic testes. The mutation may disrupt the expression of several Sertoli cell genes, including AMH and SRY, and we demonstrated severely impaired transactivation of the AMH promoter by mutant GATA4 protein. However, although the three boys in this study had very low serum AMH levels (in contrast to normal levels of testosterone), there must have been sufficient AMH produced in utero to cause regression of the Müllerian ducts. This suggests a gene dosage effect. Because the GATA4 mutation is heterozygous, the quantity of functional GATA protein produced by the single WT allele was sufficient to produce adequate levels of AMH required for the Müllerian duct regression. This is consistent with our experimental data that do not support a dominant negative effect, whereby the mutation on one allele blocks the activity of WT protein still encoded by the normal allele, resulting in a loss-offunction phenotype (Fig. 4 A and B) . We cannot exclude that the early embryonic expression of AMH may be influenced by additional factors, such as SOX9 (28) . The absence of Leydig cells (case IV.3) and presence of testicular calcifications (IV.1 and IV.2) are reminiscent of the phenotype seen in mice lacking either Amh or its receptor, and may be attributed to deficiency in AMH signaling arising from the haploinsufficiency of functional GATA4 (29) . The three affected boys had a variable clinical presentation, consistent with defects in testicular differentiation and function, and all three were raised as males.
The phenotypic variation and incomplete penetrance could be explained by genetic modifiers segregating in the family, similar to the phenotype of Gata4 ki mutant mice, which is strongly influenced by the strain background (14, 30) . Genetic modifiers may include genes that encode potential protein partners of GATA4 (such as NR5A1 and FOG2). In addition, GATA4 is known to recognize multiple gonadal promoters, and previous studies have indicated differential promoter sensitivity to GATA4 mutants in different cellular contexts (25) . In the family we describe here, GATA4 dose-dependent effects may impact differently on separate target promoters, generating the phenotypic variability.
In 46,XX heterozygous carriers of the p.Gly221Arg mutation there was no apparent ovarian phenotype. However, GATA4 is expressed in the developing ovary as well as in adult granulosa and thecal cells (5) , which suggests that either the p.Gly221Arg mutation specifically impairs testicular development or that ovarian development may be less sensitive than the testis to reduced GATA4 activity. siGata4 transgenic mice support the latter hypothesis, where the reduction of Gata4 expression in the testis is accompanied by a significant reduction of GATA4 downstream target genes. In the ovary, the expression of the target genes was minimally affected (31) .
We show that mutation in a cofactor (GATA4) of a key protein involved in gonadal development (NR5A1) is associated with human cases of DSD and CHD. The proband is also azoospermic, suggesting that the GATA4 mutation may also cause infertility. The proband has no evidence of heart anomalies, which suggests that other cases of 46,XY DSD and/or male infertility may also be due to mutations in GATA4. In this study, we show that GATA4 is required for human testicular development similar to its role in the mouse. This adds GATA4 to the limited number of genetic factors known to cause human DSD.
Materials and Methods
Complete methods are described in detail in SI Materials and Methods.
We studied a French family with a history of 46,XY DSD. Details regarding control samples are described in SI Materials and Methods. We obtained written informed consent from all patients, family members, and control subjects who participated in the study. Consent forms were approved by local ethical committees.
We sequenced the coding regions of the DMRT1, SRY, SOX9, NR5A1, NR5A2, WT1, and MAMLD1 to exclude mutations in these genes causing the gonadal anomalies (SI Materials and Methods). DNA from peripheral blood lymphocytes from case IV.2 underwent comparative genomic hybridization (CGH) analysis using the NimbleGen platform (HG18 CGH 385K WG Tiling v1.0; Roche) according to the manufacturer's recommendations.
